Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024

DOI record: { "DOI": "10.2807/1560-7917.es.2025.30.10.2400252", "ISSN": [ "1560-7917" ], "URL": "http://dx.doi.org/10.2807/1560-7917.ES.2025.30.10.2400252", "abstract": "<jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Monoclonal antibodies (mAbs) and antiviral drugs have emerged as additional tools for treatment of COVID-19.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Aim</jats:title>\n <jats:p>We aimed to review data on susceptibility of 14 SARS-CoV-2 variants to mAbs and antiviral drugs authorised in the European Union/European Economic Area (EU/EEA) countries.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>We constructed a literature review compiling 298 publications from four databases: PubMed, Science Direct, LitCovid and BioRxiv/MedRxiv preprint servers. We included publications on nirmatrelvir and ritonavir, remdesivir and tixagevimab and cilgavimab, regdanvimab, casirivimab and imdevimab, and sotrovimab approved by the European Medicines Agency (EMA) by 1 October 2024.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>The mutations identified in the open reading frame (ORF)1ab, specifically nsp5:H172Y, nsp5:H172Y and Q189E, nsp5:L50F and E166V and nsp5:L50F, E166A and L167V, led to a decrease in susceptibility to nirmatrelvir and ritonavir, ranging from moderate (25-99) to high reductions (&gt; 100). Casirivimab and imdevimab exhibited highly reduced neutralisation capacity across all Omicron sub-lineages. Sub-lineages BA.1, BA.2 and BA.5 had decreased susceptibility to regdanvimab, while sotrovimab showed decreased efficacy for BA.2, BA.4, BQ.1.1 and BA.2.86. Tixagevimab and cilgavimab exhibited highly reduced neutralisation activity against BQ.1, BQ.1.1, XBB, XBB.1.5 and BA.2.86 sub-lineages.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>The emergence of new variants, some with altered antigenic characteristics, may lead to resistance against mAbs and/or antiviral drugs and evasion of immunity induced naturally or by vaccination. This summary of mutations, combination of mutations and SARS-CoV-2 variants linked to reduced susceptibility to mAbs and antiviral drugs, should aid the selection of appropriate treatment strategies and/or phasing out therapies that have lost their effectiveness.</jats:p>\n </jats:sec>", "author": [ { "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "family": "Vukovikj", "given": "Maja", "sequence": "first" }, { "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "family": "Melidou", "given": "Angeliki", "sequence": "additional" }, { "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "family": "Nannapaneni", "given": "Priyanka", "sequence": "additional" }, { "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "family": "Normark", "given": "Tanja", "sequence": "additional" }, { "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "family": "Kraus", "given": "Annette", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0003-2693-7224", "affiliation": [ { "name": "European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden" } ], "authenticated-orcid": false, "family": "Broberg", "given": "Eeva K", "sequence": "additional" } ], "container-title": "Eurosurveillance", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 3, 14 ] ], "date-time": "2025-03-14T10:15:41Z", "timestamp": 1741947341000 }, "deposited": { "date-parts": [ [ 2025, 3, 14 ] ], "date-time": "2025-03-14T10:15:54Z", "timestamp": 1741947354000 }, "indexed": { "date-parts": [ [ 2025, 3, 15 ] ], "date-time": "2025-03-15T04:17:21Z", "timestamp": 1742012241318, "version": "3.38.0" }, "is-referenced-by-count": 0, "issue": "10", "issued": { "date-parts": [ [ 2025, 3, 13 ] ] }, "journal-issue": { "issue": "10", "published-print": { "date-parts": [ [ 2025, 3, 13 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 3, 13 ] ], "date-time": "2025-03-13T00:00:00Z", "timestamp": 1741824000000 } } ], "member": "7995", "original-title": [], "prefix": "10.2807", "published": { "date-parts": [ [ 2025, 3, 13 ] ] }, "published-print": { "date-parts": [ [ 2025, 3, 13 ] ] }, "publisher": "European Centre for Disease Control and Prevention (ECDC)", "reference": [ { "key": "r1", "unstructured": "World Health Organization (WHO). WHO COVID-19 dashboard. Geneva: WHO. [Accessed: 10 Mar 2025]. Available from: https://covid19.who.int" }, { "DOI": "10.1016/j.drup.2021.100794", "article-title": "An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.", "author": "Drożdżal", "doi-asserted-by": "crossref", "journal-title": "Drug Resist Updat", "key": "r2", "volume": "59", "year": "2021" }, { "DOI": "10.1186/s12879-021-06222-4", "article-title": "Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions.", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "496", "issue": "1", "journal-title": "BMC Infect Dis", "key": "r3", "volume": "21", "year": "2021" }, { "DOI": "10.3390/v12050526", "article-title": "SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions.", "author": "Uddin", "doi-asserted-by": "crossref", "first-page": "526", "issue": "5", "journal-title": "Viruses", "key": "r4", "volume": "12", "year": "2020" }, { "key": "r5", "unstructured": "European Centre for Disease Prevention and Control (ECDC). Case management and treatment of COVID-19. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/infectious-disease-topics/z-disease-list/covid-19/facts/case-management-and-treatment-covid-19" }, { "article-title": "Mechanism of action of small-molecule agents in ongoing clinical trials for SARS-CoV-2: a review.", "author": "Zhao", "journal-title": "Front Pharmacol", "key": "r6", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.biopha.2023.114367", "article-title": "Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?", "author": "Hashemian", "doi-asserted-by": "crossref", "journal-title": "Biomed Pharmacother", "key": "r7", "volume": "162", "year": "2023" }, { "DOI": "10.1128/CMR.00162-20", "article-title": "Remdesivir against COVID-19 and other viral diseases.", "author": "Malin", "doi-asserted-by": "crossref", "first-page": "e00162", "issue": "1", "journal-title": "Clin Microbiol Rev", "key": "r8", "volume": "34", "year": "2020" }, { "DOI": "10.1038/s41577-021-00542-x", "article-title": "Neutralizing monoclonal antibodies for treatment of COVID-19.", "author": "Taylor", "doi-asserted-by": "crossref", "first-page": "382", "issue": "6", "journal-title": "Nat Rev Immunol", "key": "r9", "volume": "21", "year": "2021" }, { "DOI": "10.1038/s41579-022-00809-7", "article-title": "SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies.", "author": "Cox", "doi-asserted-by": "crossref", "first-page": "112", "issue": "2", "journal-title": "Nat Rev Microbiol", "key": "r10", "volume": "21", "year": "2023" }, { "key": "r11", "unstructured": "Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Evusheld ™ (tixagevimab co-packaged with cilgavimab). Silver Spring: FDA; 2023. Revoked: 26 Jan 2023. Available from: https://www.fda.gov/media/154701/download" }, { "DOI": "10.1038/s41591-022-01911-2", "article-title": "Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.", "author": "Tegally", "doi-asserted-by": "crossref", "first-page": "1785", "issue": "9", "journal-title": "Nat Med", "key": "r12", "volume": "28", "year": "2022" }, { "DOI": "10.1038/s41586-022-04980-y", "article-title": "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "593", "issue": "7923", "journal-title": "Nature", "key": "r13", "volume": "608", "year": "2022" }, { "DOI": "10.1016/S1473-3099(22)00365-6", "article-title": "Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.", "author": "Yamasoba", "doi-asserted-by": "crossref", "first-page": "942", "issue": "7", "journal-title": "Lancet Infect Dis", "key": "r14", "volume": "22", "year": "2022" }, { "DOI": "10.1038/s41586-021-03944-y", "article-title": "SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.", "author": "Mlcochova", "doi-asserted-by": "crossref", "first-page": "114", "issue": "7883", "journal-title": "Nature", "key": "r15", "volume": "599", "year": "2021" }, { "key": "r16", "unstructured": "European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 10 Mar 2025]. Available from: https://erviss.org/" }, { "key": "r17", "unstructured": "European Centre for Disease Prevention and Control (ECDC) and World Health Organization Regional Office for Europe (WHO/Europe). Technical guidance for antigenic SARS-CoV-2 monitoring. Stockholm: ECDC and Copenhagen: WHO/Europe; Jun 2022 Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Antigenic-SARS-CoV-2-monitoring-Joint-ECDC-WHO-report-June-2022.pdf" }, { "DOI": "10.1128/JCM.02504-20", "article-title": "Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera.", "author": "Perera", "doi-asserted-by": "crossref", "first-page": "e02504", "issue": "2", "journal-title": "J Clin Microbiol", "key": "r18", "volume": "59", "year": "2021" }, { "DOI": "10.1038/s41596-021-00536-y", "article-title": "Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays.", "author": "Bewley", "doi-asserted-by": "crossref", "first-page": "3114", "issue": "6", "journal-title": "Nat Protoc", "key": "r19", "volume": "16", "year": "2021" }, { "DOI": "10.2807/1560-7917.ES.2020.25.16.2000421", "article-title": "Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.", "author": "Perera", "doi-asserted-by": "crossref", "issue": "16", "journal-title": "Euro Surveill", "key": "r20", "volume": "25", "year": "2020" }, { "DOI": "10.1371/journal.pone.0261045", "article-title": "Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.", "author": "Tzou", "doi-asserted-by": "crossref", "issue": "3", "journal-title": "PLoS One", "key": "r21", "volume": "17", "year": "2022" }, { "article-title": "Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer.", "author": "Wright", "issue": "1", "journal-title": "Virus Evol", "key": "r22", "volume": "8", "year": "2022" }, { "key": "r23", "unstructured": "European Medicines Agency (EMA). Annex I - Summary of product characteristics, Regkirona. Amsterdam: EMA; 12 Nov 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf" }, { "key": "r24", "unstructured": "European Medicines Agency (EMA). Annex I - Summary of product characteristics, Evusheld. Amsterdam: EMA; 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf" }, { "key": "r25", "unstructured": "Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization (EUA) of Regen-CoV® (casirivimab and imdevimab). Silver Spring: FDA; 2021. Revoked: 13 Dec 2024. Available from: https://www.fda.gov/media/145611/download" }, { "key": "r26" }, { "key": "r27", "unstructured": "European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non-systematic literature review for surveillance purposes. Stockholm: ECDC; Jul 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2_variant_mutations_conferring_reduced_susceptibility_to_antiviral_drugs_and_monoclonal_antibodies.pdf" }, { "article-title": "The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2.", "author": "Cathcart", "journal-title": "bioRxiv", "key": "r28", "year": "2022" }, { "DOI": "10.1021/acscentsci.3c00538", "article-title": "Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir.", "author": "Hu", "doi-asserted-by": "crossref", "first-page": "1658", "issue": "8", "journal-title": "ACS Cent Sci", "key": "r29", "volume": "9", "year": "2023" }, { "DOI": "10.1021/acs.jcim.3c00344", "article-title": "Integrative approach to dissect the drug resistance mechanism of the H172Y mutation of SARS-CoV-2 main protease.", "author": "Clayton", "doi-asserted-by": "crossref", "first-page": "3521", "issue": "11", "journal-title": "J Chem Inf Model", "key": "r30", "volume": "63", "year": "2023" }, { "DOI": "10.1038/s44259-023-00009-0", "article-title": "Rapid resistance profiling of SARS-CoV-2 protease inhibitors.", "author": "Moghadasi", "doi-asserted-by": "crossref", "first-page": "9", "issue": "1", "journal-title": "NPJ Antimicrob Resist", "key": "r31", "volume": "1", "year": "2023" }, { "DOI": "10.1074/jbc.AC120.015720", "article-title": "Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.", "author": "Tchesnokov", "doi-asserted-by": "crossref", "first-page": "16156", "issue": "47", "journal-title": "J Biol Chem", "key": "r32", "volume": "295", "year": "2020" }, { "DOI": "10.1056/NEJMc2119407", "article-title": "Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant.", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "995", "issue": "10", "journal-title": "N Engl J Med", "key": "r33", "volume": "386", "year": "2022" }, { "DOI": "10.1038/s41586-022-04474-x", "article-title": "Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.", "author": "Meng", "doi-asserted-by": "crossref", "first-page": "706", "issue": "7902", "journal-title": "Nature", "key": "r34", "volume": "603", "year": "2022" }, { "article-title": "SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique spike binding properties.", "author": "Fenwick", "journal-title": "bioRxiv", "key": "r35", "year": "2022" }, { "DOI": "10.1016/S1473-3099(22)00416-9", "article-title": "Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.", "author": "Herman", "doi-asserted-by": "crossref", "first-page": "1444", "issue": "10", "journal-title": "Lancet Infect Dis", "key": "r36", "volume": "22", "year": "2022" }, { "DOI": "10.1038/s41591-021-01678-y", "article-title": "An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.", "author": "VanBlargan", "doi-asserted-by": "crossref", "first-page": "490", "issue": "3", "journal-title": "Nat Med", "key": "r37", "volume": "28", "year": "2022" }, { "DOI": "10.1016/j.intimp.2022.108570", "article-title": "Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.", "author": "Lee", "doi-asserted-by": "crossref", "journal-title": "Int Immunopharmacol", "key": "r38", "volume": "106", "year": "2022" }, { "DOI": "10.1056/NEJMc2207519", "article-title": "Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants.", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "468", "issue": "5", "journal-title": "N Engl J Med", "key": "r39", "volume": "387", "year": "2022" }, { "DOI": "10.1016/j.antiviral.2023.105638", "article-title": "Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.", "author": "Driouich", "doi-asserted-by": "crossref", "journal-title": "Antiviral Res", "key": "r40", "volume": "215", "year": "2023" }, { "DOI": "10.1038/s41467-022-31615-7", "article-title": "Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.", "author": "Case", "doi-asserted-by": "crossref", "first-page": "3824", "issue": "1", "journal-title": "Nat Commun", "key": "r41", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.jinf.2022.06.033", "article-title": "Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2.", "author": "Martin-Blondel", "doi-asserted-by": "crossref", "first-page": "e104", "issue": "4", "journal-title": "J Infect", "key": "r42", "volume": "85", "year": "2022" }, { "DOI": "10.1007/s40121-022-00755-0", "article-title": "Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA.", "author": "Cheng", "doi-asserted-by": "crossref", "first-page": "607", "issue": "2", "journal-title": "Infect Dis Ther", "key": "r43", "volume": "12", "year": "2023" }, { "DOI": "10.1016/S1473-3099(23)00575-3", "article-title": "Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.", "author": "Uriu", "doi-asserted-by": "crossref", "first-page": "e460", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "r44", "volume": "23", "year": "2023" }, { "DOI": "10.1016/S1473-3099(23)00588-1", "article-title": "Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.", "author": "Sheward", "doi-asserted-by": "crossref", "first-page": "e462", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "r45", "volume": "23", "year": "2023" }, { "DOI": "10.1016/S1473-3099(23)00573-X", "article-title": "Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.", "author": "Yang", "doi-asserted-by": "crossref", "first-page": "e457", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "r46", "volume": "23", "year": "2023" }, { "DOI": "10.1038/s41598-021-03154-6", "article-title": "Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.", "author": "Huang", "doi-asserted-by": "crossref", "first-page": "23921", "issue": "1", "journal-title": "Sci Rep", "key": "r47", "volume": "11", "year": "2021" }, { "DOI": "10.1128/JCM.00527-21", "article-title": "Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays.", "author": "Sholukh", "doi-asserted-by": "crossref", "issue": "10", "journal-title": "J Clin Microbiol", "key": "r48", "volume": "59", "year": "2021" }, { "DOI": "10.1016/S0140-6736(21)00527-4", "article-title": "WHO International Standard for anti-SARS-CoV-2 immunoglobulin.", "author": "Kristiansen", "doi-asserted-by": "crossref", "first-page": "1347", "issue": "10282", "journal-title": "Lancet", "key": "r49", "volume": "397", "year": "2021" } ], "reference-count": 49, "references-count": 49, "relation": {}, "resource": { "primary": { "URL": "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.10.2400252" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024", "type": "journal-article", "update-policy": "https://doi.org/10.2807/1560-7917.es.crp2020", "volume": "30" }